Posted by Michael Wonder on 13 Aug 2020
Innovent and Eli Lilly announce acceptance of a supplemental new drug application of Tyvyt (sintilimab injection) in combination with gemcitabine and platinum as first-line therapy in squamous non-small cell lung cancer in China
12 August 2020 - Innovent Biologics today jointly announced with Eli Lilly that the National Medical Products Administration of China has accepted the supplemental new drug application for Tyvyt (sintilimab injection) in combination with Gemzar (gemcitabine) and platinum as first-line therapy in squamous non-small cell lung cancer.
Recently, the NMPA accepted a supplemental new drug application for Tyvyt (sintilimab injection) as first-line therapy in non-squamous non-small cell lung cancer on 23 April 2020.
